Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Clinical trial NCT05309187 · COMPLETED

Trial details

NCT number: NCT05309187
Sponsor: Immune-Onc Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor, Adult

Start date: 2022-04-11
Primary completion: 2024-03-29
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.